Triple-Negative Breast Cancer

DBCOND0068542NeoplasmsSkin and Subcutaneous Tissue Diseases

Triple-Negative Breast Cancer is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
Triple-Negative Breast Cancer (TNBC) · ER-Negative PR-Negative HER2-Negative Breast Cancer · Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative · TNBC · Triple Negative Breast Cancer(TNBC)
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0583085SNOMED CT706970001MedDRA10075566UMLSC3539878

What you can answer from here — as of November 01, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
746Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Triple-Negative Breast Cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In